"Two-Stage Rocket-Propelled" Strategy Boosting Theranostic Efficacy with Mitochondria-Specific Type I-II Photosensitizers

Modulating Aggregation and Deaggregation Based on Assembling Strategy to Switch on NIR-II Light-Excited Fluorescence for Self-Reporting Viability of Eliminating Cancer Cell

The fabrication of self-reporting photosensitizers (PSs), enabling real-time evaluation of the extent of elimination of cancer cells, holds significant scientific importance in the photodynamic therapy (PDT) process. To address the intrinsic challenge of the short-wavelength light source, this work proposed an innovative approach of rational design second near-infrared (NIR-II, 1000-1700 nm) light-excited fluorescent PS systems (named HOEt-PI, Me-PI, and Et-PI, respectively) through modulating aggregation and deaggregation based on assembling strategy. Therein, the suitable interplanar distance of adjacent Et-PI linked with C-H···π interactions was an idea for relieving compact π···π packing for fluorescent imaging as well as elevating the spin-orbit coupling for reactive oxygen species (ROS) generation. With ROS continuously increasing, Et-PI underwent cell membrane-to-mitochondria migration, ultimately accumulated in nucleoli, symbolizing programmed cell death, thus distinguishing dead/live cells via three-photon fluorescence imaging (excited on 1250 nm) under photogeneration ROS. Meaningfully, the three-photon fluorescence of Et-PI was triggered by RNA of nucleoli, for which the higher signal-to-noise ratio and in-depth fluorescence imaging observed cancer cellular viability. Collectively, the proposed findings presented a constructing strategy for NIR-II light-mediated self-reporting PS for guiding the PDT of deep cancerous tissue in the future.

Induced Ferroptosis Pathway by Regulating Cellular Lipid Peroxidation With Peroxynitrite Generator for Reversing "Cold" Tumors

Overcoming the resistance of tumor cells to apoptosis and immunosuppression is an important challenge to improve tumor immunotherapy. Non-apoptotic death mode of ferroptosis has been regarded as a new strategy to enhance tumor immunotherapy against drug-resistant cancers. The lethal accumulation of lipid peroxides (LPO) determines the progress of ferroptosis. The high susceptibleness of ferroptosis provides an opportunity for combating triple-negative breast cancer. Reactive nitrogen species (RNS) produced by nitric oxide (NO) and reactive oxygen species (ROS) is more lethal than ROS for tumor cells. Herein, an RNS-mediated immunotherapy strategy for inducing ferroptosis pathway is proposed by improving LPO accumulation, and constructed a multifunctional liposome (Lipo-MT-SNAP) comprised of peroxynitrite (ONOO-) generator, tumor targeted group, inhibiting glutathione peroxidase 4 (GPX4), and basic units (dipalmitoyl phosphatidylcholine and cholesterol). The significant enhancement of LPO resulted from the intense oxidative damage of ONOO- impaired synthesis of GPX4 by depleting glutathione, which further amplified ferroptosis and triggered immunogenic cell death. In vivo, RNS-mediated photoimmunotherapy can promote polarization of M2 to M1 macrophages and dendritic cells maturation, further infiltrate T cells, regulate the secretion of inflammatory factors, and reprogram the tumor microenvironment. The powerful RNS-mediated ferroptosis induces strong immunogenicity and effectively inhibit tumor proliferation.

PEGylated BODIPY Photosensitizer for Type I Dominant Photodynamic Therapy and Afterglow Imaging

Type I photodynamic therapy (PDT) exhibits outstanding therapeutic effects in hypoxic environments in tumors, but the design of type I photosensitizers (PSs), especially those with simple structures but dramatic properties, remains a challenge. Herein, we report a design strategy for developing type I PSs in one molecule with afterglow luminescence. As a proof concept, a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) PS (BIP) bearing water-soluble poly(ethylene glycol) (mPEG550) chains is synthesized, and BIP can self-assemble into nanoparticles (BIPNs). Interestingly, BIPNs exhibit an O2•--triggered afterglow luminescence, which is scarce, especially for BODIPY derivatives. BIPNs demonstrate outstanding type I dominant PDT at an ultralow dose under both hypoxic and normoxic environments, which can significantly inhibit tumor growth under irradiation. This work highlights a high-performance PS with afterglow luminescence and excellent PDT effects, underscoring the significant potential of versatile PSs in clinical tumor theranostics.

Coumarin-Based ACQ-AIE Conversion Photosensitizer for Mitochondrial Imaging and Synergistic Cancer Therapy

Most of the traditional fluorescent molecules have the advantages of high fluorescence quantum yield, good stability, and excellent structural adjustability, but they exhibit the characteristics of fluorescence quenching caused by aggregation, which restricts their application in aqueous solutions or solids. The excellent luminescence properties and photosensitive potential of aggregation-induced emission (AIE) materials in a condensed state have made them widely concerned in the scientific research field, so it is very challenging to regulate the transformation of traditional aggregation-caused quenching (ACQ) fluorophores into AIE fluorophores. In this study, the traditional coumarin fluorophore was used as a matrix. After conjugating the triphenylamine AIE group, the triphenylphosphine cation was linked through the alkyl chain to obtain a molecular probe NCTPP with excellent AIE characteristic, water solubility, mitochondrial green light imaging, chemotherapy and photodynamic therapy capabilities. As far as we know, it was the first time that the photosensitivity of coumarin fluorescent molecules was imparted by the ACQ-AIE conversion method.

Win-win integration: A mitochondria targeted AIE photosensitizer for hypochlorite detection and type I & type II photodynamic therapy

BACKGROUND

Photodynamic therapy (PDT) is a pioneering and effective anticancer modality with low adverse effects and high selectivity. Hypochlorous acid or hypochlorite (HClO/ClO-) is a type of inflammatory cytokine. The abnormal increase of ClO- in tumor cells is related to tumor pathogenesis and may be a "friend" for the design and synthesis of responsive phototherapy agents. However, preparing responsive phototherapy agents for all-in-one noninvasive diagnosis and simultaneous in situ therapy in a complex tumor environment is highly desirable but still remains an enormously demanding task.

RESULTS

An acceptor-π bridge-donor-π bridge-acceptor (A-π-D-π-A) type photosensitizer TPTPy was designed and synthesized based on the phenothiazine structure which was used as the donor moiety as well as a ClO- responsive group. TPTPy was a multifunctional mitochondria targeted aggregation-induced emission (AIE) photosensitizer which could quickly and sensitively respond to ClO- with fluorescence "turn on" performance (19-fold fluorescence enhancement) and enhanced type I reactive oxygen species (ROS) generation to effectively ablate hypoxic tumor cells. The detection limit of TPTPy to ClO- was calculated to be 185.38 nM. The well-tailored TPTPy anchoring to mitochondria and producing ROS in situ could disrupt mitochondria and promote cell apoptosis. TPTPy was able to image inflammatory cells and tumor cells through ClO- response. In vivo results revealed that TPTPy was successfully utilized for PDT in tumor bearing nude mice and exhibited excellent biological safety for major organs.

SIGNIFICANCE AND NOVELTY

A win-win integration strategy was proposed to design a tumor intracellular ClO- responsive photosensitizer TPTPy capable of both type I and type II ROS production to achieve photodynamic therapy of tumor. This work sheds light on the win-win integration design by taking full advantage of the characteristics of tumor microenvironment to build up responsive photosensitizer for in situ PDT of tumor.

Heavy-atom-free π-twisted photosensitizers for fluorescence bioimaging and photodynamic therapy

As the field of preclinical research on photosensitizers (PSs) for anticancer photodynamic therapy (PDT) continues to expand, a focused effort is underway to develop agents with innovative molecular structures that offer enhanced targeting, selectivity, activation, and imaging capabilities. In this context, we introduce two new heavy-atom-free PSs, DBXI and DBAI, characterized by a twisted π-conjugation framework. This innovative approach enhances the spin-orbit coupling (SOC) between the singlet excited state (S1) and the triplet state (T1), resulting in improved and efficient intersystem crossing (ISC). Both PSs are highly effective in producing reactive oxygen species (ROS), including singlet oxygen and/or superoxide species. Additionally, they also demonstrate remarkably strong fluorescence emission. Indeed, in addition to providing exceptional photocytotoxicity, this emissive feature, generally lacking in other reported structures, allows for the precise monitoring of the PSs' distribution within specific cellular organelles even at nanomolar concentrations. These findings underscore the dual functionality of these PSs, serving as both fluorescent imaging probes and light-activated therapeutic agents, emphasizing their potential as versatile and multifunctional tools in the field of PDT.

A review on ferroptosis and photodynamic therapy synergism: Enhancing anticancer treatment

Ferroptosis is an iron-dependent programmed cell death modality, which has showed great potential in anticancer treatment. Photodynamic therapy (PDT) is widely used in clinic as an anticancer therapy. PDT combined with ferroptosis-promoting therapy has been found to be a promising strategy to improve anti-cancer therapy efficacy. Fenton reaction in ferroptosis can provide oxygen for PDT, and PDT can produce reactive oxygen species for Fenton reaction to enhance ferroptosis. In this review, we briefly present the importance of ferroptosis in anticancer treatment, mechanism of ferroptosis, researches on PDT induced ferroptosis, and the mechanism of the synergistic effect of PDT and ferroptosis on cancer killing.